Assess for signs and symptoms of influenza (fever, dyspnea, tachypnea, tachycardia, hypotension) prior to and at least daily during therapy. Patient must be symptomatic for no more than 2 days to receive peramivir.
Monitor for signs of neuropsychiatric symptoms (hallucinations, delirium, abnormal behavior) during therapy.
Assess patient for skin rash during therapy. Monitor closely and treat symptomatically.
Lab Test Considerations:
May cause ↑ serum ALT, AST, glucose, creatine phosphokinase, and ↓ neutrophils.
Intermittent Infusion: Diluent: 0.9% NaCl or 0.45% NaCl, D5, or LR to a maximum volume of 100 mL. Solution is clear and colorless; do not administer solution that is discolored or contains a precipitate. Upon dilution, administer immediately or refrigerate up to 24 hrs; discard after 24 hrs. Allow to reach room temperature prior to administration. Discard unused portion of single use vial.
Rate: Infuse over 15 to 30 min.
Y-Site Incompatibility: Do not administer simultaneously with any other medication.
Explain purpose of peramivir to patient.
Advise patient to notify health care professional if signs and symptoms of anaphylaxis or rash, or neuropsychiatric symptoms occur.
Advise female patient to notify health care professional if pregnancy is planned or suspected or if breastfeeding.
Resolution of sign and symptoms of influenza.
peramivir is a sample topic from the Davis's Drug Guide.
Emergency Central is a collection of disease, drug, and test information including 5-Minute Emergency Medicine Consult, Davis’s Drug, McGraw-Hill Medical’s Diagnosaurus®, Pocket Guide to Diagnostic Tests, and MEDLINE Journals created for emergency medicine professionals. Learn more.